RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Huaren Pharmaceutical Co Stock

Huaren Pharmaceutical Co EBIT 2025

Huaren Pharmaceutical Co EBIT

286.11 M CNY

Ticker

300110.SZ

ISIN

CNE100000SW1

In 2025, Huaren Pharmaceutical Co's EBIT was 286.11 M CNY, a 13.55% increase from the 251.97 M CNY EBIT recorded in the previous year.

The Huaren Pharmaceutical Co EBIT history

YEAREBIT (undefined CNY)
2023286.11
2022251.97
2021213.47
2020121
201997.6
201874
2017100.5
201682.6
201580.2
2014102.2
2013164.3
2012116.1
201189.3
201093.8
200987
200862.7
200745.7

Huaren Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Huaren Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Huaren Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Huaren Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Huaren Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Huaren Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Huaren Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Huaren Pharmaceutical Co’s growth potential.

Huaren Pharmaceutical Co Revenue, EBIT and net profit per share

DateHuaren Pharmaceutical Co RevenueHuaren Pharmaceutical Co EBITHuaren Pharmaceutical Co Net Income
20231.64 B CNY286.11 M CNY188.06 M CNY
20221.62 B CNY251.97 M CNY180.82 M CNY
20211.56 B CNY213.47 M CNY130.4 M CNY
20201.62 B CNY121 M CNY94.6 M CNY
20191.46 B CNY97.6 M CNY42.1 M CNY
20181.38 B CNY74 M CNY38.8 M CNY
20171.31 B CNY100.5 M CNY37.5 M CNY
20161.25 B CNY82.6 M CNY23.9 M CNY
20151.11 B CNY80.2 M CNY22.9 M CNY
2014916.8 M CNY102.2 M CNY56.2 M CNY
2013867.2 M CNY164.3 M CNY121.5 M CNY
2012562 M CNY116.1 M CNY96.6 M CNY
2011405.3 M CNY89.3 M CNY87.6 M CNY
2010338.3 M CNY93.8 M CNY76.3 M CNY
2009288.5 M CNY87 M CNY60.8 M CNY
2008207.6 M CNY62.7 M CNY46.4 M CNY
2007161.1 M CNY45.7 M CNY34.1 M CNY

Huaren Pharmaceutical Co stock margins

The Huaren Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Huaren Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Huaren Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Huaren Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Huaren Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Huaren Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Huaren Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Huaren Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Huaren Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Huaren Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Huaren Pharmaceutical Co Margin History

Huaren Pharmaceutical Co Gross marginHuaren Pharmaceutical Co Profit marginHuaren Pharmaceutical Co EBIT marginHuaren Pharmaceutical Co Profit margin
202342.53 %17.49 %11.49 %
202242.97 %15.56 %11.16 %
202148.7 %13.68 %8.35 %
202034.31 %7.49 %5.85 %
201956.11 %6.68 %2.88 %
201857.37 %5.35 %2.8 %
201752.91 %7.66 %2.86 %
201644.65 %6.61 %1.91 %
201544.39 %7.25 %2.07 %
201447.89 %11.15 %6.13 %
201353 %18.95 %14.01 %
201256.16 %20.66 %17.19 %
201155.24 %22.03 %21.61 %
201055.42 %27.73 %22.55 %
200956.29 %30.16 %21.07 %
200851.88 %30.2 %22.35 %
200744.63 %28.37 %21.17 %

Huaren Pharmaceutical Co Aktienanalyse

What does Huaren Pharmaceutical Co do?

Huaren Pharmaceutical Co. Ltd is a leading Chinese pharmaceutical company based in Beijing. It was founded in 1996 and has since experienced impressive growth. The company is listed on the Shanghai Stock Exchange under the ticker symbol SHA:600664. Huaren Pharmaceutical's history is characterized by a smart corporate strategy and a strong focus on customer needs. The company started as a small family business and built a strong presence in the Chinese market in the following years. This involved establishing innovative strategic partnerships with other companies in the industry. In 2010, the company went public, further accelerating its growth. The business model of Huaren Pharmaceutical is based on a wide product portfolio, including various products in the pharmaceutical, healthcare, and biotechnology industries. The company works closely with international experts and scientific institutes to ensure the highest quality and effectiveness of its products. It is active in research and development, production, and distribution of healthcare products and services, and has built strong industry expertise. The different divisions of Huaren Pharmaceutical include the production of antibiotics, vitamin complexes, painkillers, and vaccines. The company is also involved in diagnostic, hospital care, and medical device sectors. Another important division is the production of generics, which makes the company one of the major players in the Chinese generic drug market. Huaren Pharmaceutical takes pride in providing a comprehensive range of products for patients. Its key products include anti-cancer therapies, medications for nervous system disorders, cardiovascular diseases, and vascular diseases. The company has state-of-the-art research and development departments that ensure its products are always at the forefront of technology and meet customer needs. Due to its innovation capabilities, Huaren Pharmaceutical has won numerous awards and patents. The company aims to solidify its market leadership in China while expanding its presence in the Asian and global pharmaceutical markets. It also intends to focus on the biotechnology market and expand its research and development activities. With this strategic approach, Huaren Pharmaceutical aims to remain a significant player in the Chinese pharmaceutical industry and drive advancements and technologies in healthcare. Huaren Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Huaren Pharmaceutical Co's EBIT

Huaren Pharmaceutical Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Huaren Pharmaceutical Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Huaren Pharmaceutical Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Huaren Pharmaceutical Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Huaren Pharmaceutical Co stock

How much did Huaren Pharmaceutical Co achieve in EBIT for the current year?

In the current year, Huaren Pharmaceutical Co has achieved an EBIT of 286.11 M CNY.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Huaren Pharmaceutical Co.

How has the EBIT of Huaren Pharmaceutical Co developed in recent years?

The EBIT of Huaren Pharmaceutical Co has increased by 13.552% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Huaren Pharmaceutical Co?

The EBIT of Huaren Pharmaceutical Co is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Huaren Pharmaceutical Co pay?

Over the past 12 months, Huaren Pharmaceutical Co paid a dividend of 0.02 CNY . This corresponds to a dividend yield of about 0.64 %. For the coming 12 months, Huaren Pharmaceutical Co is expected to pay a dividend of 0.02 CNY.

What is the dividend yield of Huaren Pharmaceutical Co?

The current dividend yield of Huaren Pharmaceutical Co is 0.64 %.

When does Huaren Pharmaceutical Co pay dividends?

Huaren Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of July, July, August, August.

How secure is the dividend of Huaren Pharmaceutical Co?

Huaren Pharmaceutical Co paid dividends every year for the past 7 years.

What is the dividend of Huaren Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 0.02 CNY are expected. This corresponds to a dividend yield of 0.64 %.

In which sector is Huaren Pharmaceutical Co located?

Huaren Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Huaren Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Huaren Pharmaceutical Co from 7/10/2024 amounting to 0.021 CNY, you needed to have the stock in your portfolio before the ex-date on 7/10/2024.

When did Huaren Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 7/10/2024.

What was the dividend of Huaren Pharmaceutical Co in the year 2024?

In the year 2024, Huaren Pharmaceutical Co distributed 0.018 CNY as dividends.

In which currency does Huaren Pharmaceutical Co pay out the dividend?

The dividends of Huaren Pharmaceutical Co are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Huaren Pharmaceutical Co

Our stock analysis for Huaren Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Huaren Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.